New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
D-150 gene therapy enters pivotal Wet-AMD/DME trials, cutting injections up to 89%. Click for this FDMT update.
A novel intravitreal axitinib hydrogel demonstrated durable disease control in patients with treatment-naive neovascular age-related macular degeneration (AMD), with superior maintenance of visual ...
ALPHARETTA, Ga., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
-- More than half of patients free of injection at median follow-up of 1.7 years at 2 x 10^11 vg/eye -- “We have now followed all wet AMD patients in the OPTIC trial for a minimum of a year, and in ...
Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...
Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results